The 7 Weight Loss Claims the FTC Calls Always False

what are the seven claims on the ftc's gut check list?

The seven claims come straight from FTC's Gut Check guide, published in January 2014 for reporters and media buyers vetting weight-loss advertising before it runs. FTC calls them representations that "experts say simply can't be true" — not claims awaiting evidence, but claims the agency has already decided fail.

Four of the seven still anchor familiar ad archetypes running right now.

• Causes weight loss of two pounds or more a week for a month or more without dieting or exercise
• Causes substantial weight loss no matter what or how much the consumer eats
• Causes permanent weight loss even after the consumer stops using the product
• Blocks the absorption of fat or calories to enable consumers to lose substantial weight
• Safely enables consumers to lose more than three pounds a week for more than four weeks
• Causes substantial weight loss for all users
• Causes substantial weight loss by wearing a product on the body or rubbing it into the skin

why does the ftc treat these as false rather than unsubstantiated?

FTC treats them as false rather than unsubstantiated because it built the list around physical limits it says no legitimate product exceeds, not around thin evidence a better study might fix later. The distinction matters for how you defend a claim: "we need more data" works against an unsubstantiated-claims charge, and it doesn't work at all against one FTC has already labeled physiologically implausible.

The threshold behind the list is exact, not vague. FTC's guide defines "substantial weight loss" as a pound a week sustained for more than four weeks, or more than 15 pounds lost in any period — the line we track in more depth on what counts as substantial weight loss to the FTC.

Paraphrase doesn't launder the claim, either. FTC's own guide states that "advertisers can convey that 'substantial weight loss' message without using specific numbers," and it names dress size, inches and body-fat percentage as equivalent triggers, so "drop two dress sizes" carries the same exposure as "20 pounds in a month."

which of the seven still show up in creative running today?

Four of the seven map directly onto creative still running today: the absorption blocker, the no-effort promise, the permanence promise, and the topical or wearable route. The other three — the specific three-pounds-a-week ceiling, the eat-anything variant, and the flat "works for everyone" line — surface less often, mostly because a specific number is easier for a reviewer to catch on a first read.

None of the four needs a lawyer to spot. Each one is quoted, word for word, in the guide FTC published for reporters.

does an absorption-blocker or wearable angle have any surviving version?

A narrow version survives, but only once the outcome promise is stripped out. An ingredient can describe a documented digestive mechanism — fiber binding, delayed gastric emptying — without claiming it "blocks absorption to enable substantial weight loss," which is the exact phrase on FTC's list.

Even that narrower claim needs randomized, controlled human trial evidence to survive a challenge, and one positive study is not the same as enough evidence. Many buyers assume a single clinical trial behind an ingredient clears the bar; FTC's own guidance describes a case where two positive double-blind studies lost to a single well-controlled 12-week trial showing no significant difference, because the agency weighs the whole body of evidence rather than counting studies in the advertiser's favor.

The wearable route survives least of all. Google's Unreliable claims policy bars "claims that entice the user with an improbable result (even if this result is possible) as the likely outcome a user can expect," and a patch or wrap promising fat loss through skin contact alone reads like the textbook example of exactly that.

Guaranteed-results copy on Google also needs an accessible refund policy attached, a requirement most patch and wrap offers skip entirely — a gap our page on Google's unreliable-claims rule for diet offers walks through.

what happens to a substantiation defense once a claim is on this list?

A substantiation defense collapses immediately, because FTC has already decided these seven don't require case-by-case testing to be called false. You can't out-cite a claim the agency treats as settled; you can only stop making it.

The "results not typical" fallback is dead too, and FTC's Health Products Compliance Guidance shows exactly why. Its Example 41 describes a before-and-after ad quoting a woman who lost 16 pounds in eight weeks, with a fine-print asterisk reading "results not typical," against a randomized trial showing an average of only four pounds over placebo. FTC called the disclosure inadequate and prescribed the actual fix itself: a prominent, adjacent statement of the real study average, not a footnote.

Diet and exercise disclosure is the trap almost every clinical-trial-backed claim in this vertical falls into, because nearly every study behind a weight-loss ingredient runs on top of a caloric deficit the ad never mentions. FTC's Example 8 describes a supplement citing a placebo-controlled trial showing 12 pounds lost over eight weeks, where "both the control and test subjects engaged in regular exercise and followed a restricted-calorie diet as part of the study regimen." The agency's conclusion is the operating rule for the whole niche: "The ad should make clear that users of the supplement also will need to reduce calories and engage in regular exercise to achieve similar results." Skip that line, and a genuinely well-run study still produces a deceptive ad.

A disclaimer never rescues a claim FTC has already called false.

how do these seven map onto standard vsl and advertorial structures?

They map onto the proof stack more than the headline. The seven claims tend to surface in testimonial and before/after segments rather than a video's opening hook — a VSL, the long-form video sales pitch, can open with vague energy-and-confidence language and still end with a viewer testimonial claiming "three pounds a week for two months," landing inside claim five by the closing minutes.

The proof stack is also where FTC has actually caught operators, not the copywriting. FTC's first case challenging fake paid reviews on an independent retail site, brought against Cure Encapsulations, involved a garcinia cambogia weight-loss supplement, and the fake five-star Amazon reviews did work the ad copy legally couldn't do on its own. An advertorial, ad copy formatted as editorial content, runs the identical risk once its "reader comments" are written in-house.

FTC's own account of who falls for this names the mechanism directly: scammers lean on the reputation of the media outlet carrying the ad, betting a viewer's trust in the channel transfers to the product itself. The person who bought that placement carries exposure too, which is the liability question we cover on can affiliates get sued for false claims.

what should a buyer swap in when an offer's hook is on the list?

Swap the absolute promise for the qualified version FTC has already tolerated: name the actual study average instead of the best individual result, state the diet-and-exercise condition the trial ran under, and drop any "no matter what you eat" framing entirely. None of that costs you the sales copy's energy. It just moves the claim off a list FTC has already decided is indefensible.

Check the product before you check the copy. FDA's Tainted Weight Loss Products database is updated continuously and lists products found to contain undeclared drug ingredients — Detoxi Slim, Lipofit Extreme 2.0 Fat Burner and FATZorb all appeared on it in 2025 and 2026 alone.

That listing attaches to the SKU, the specific product listing, independent of how careful the landing page reads, which is why we walk through the supply-chain side of this separately on FDA's tainted weight-loss list as a supplier risk.

One thing we could not verify: the actual age distribution or prior-attempt rate of buyers in this vertical. CDC and NIH's own supplement-use datasets were unreachable during our research, and the honest fix is pulling CDC's National Center for Health Statistics data directly, rather than repeating the round numbers that circulate in competitor decks.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Is the Weight Loss Niche Saturated? What Ad Data Shows, Next Big Nutra Niches: Early Scaling Signals (2026), LATAM Nutra Offers: Spanish Funnels Scaling in 2026, Nutra Offers That Convert in Brazil: 2026 Ad Signals, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.